English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

J&J in Pursuit of China Pharma Acquisitions

Apr. 30, 2012

Johnson & Johnson is actively pursuing M&A in China as a way of keeping its revenue growth at least equal to the general rise in China’s pharmaceutical market – which J&J estimates to be 17%. J&J is especially interested in companies that would add products to its portfolio of mental health drugs and cancer treatments. Unlike some of its big pharma competitors, the company is not branching out into generic drugs as a way to increase China revenues.